Argenx (ARGX) Outlook Improves on Autoimmune Pipeline Expansion

Read full story on finance.yahoo.com
Argenx (ARGX) Outlook Improves on Autoimmune Pipeline Expansion
AI disclosure

Summary

Argenx SE (NASDAQ:ARGX) ranks among the most profitable biotech stocks to buy now. On April 14, TD Cowen maintained its Buy rating and $1,146 price target for A...

Original reporting

Open original source

Related coverage

Read full article on finance.yahoo.com